Trial Profile
An Open-Label, Multicenter, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary) ; Capecitabine; Regorafenib
- Indications Breast cancer; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 18 May 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
- 18 May 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2024.
- 06 Jul 2022 Status changed from recruiting to active, no longer recruiting.